A.L. PHARMA ANNOUNCES FDA APPROVALS.FORT LEE, N.J.--(BUSINESS WIRE)--June 22, 1995--A.L. Pharma Inc. (NYSE NYSE See: New York Stock Exchange :ALO) today announced that its U.S. Pharmaceuticals Division which manufactures and markets specialty generic pharmaceuticals has received approval from the Food and Drug Administration to manu- facture fac·ture n. The manner in which something, especially a work of art, is made: "the gummy surfaces, spectral smudges and woozy contours that . . . and market Fluocinonide Cream USP USP - unique sales point , 0.05% (Emulsified Base). Fluocinonide Cream (Emulsified Base) is the generic equivalent of the branded prescription product Lidex -E Cream 0.05% which has a branded market of approximately $7 million. The Company's U.S. Pharmaceuticals Division plans to begin marketing this product in the third quarter of this year. This approval is the second ANDA ANDA abbr. abbreviated new drug application product approval the Company's U.S. Pharmaceuticals Division has received in 1995. In late February, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals for Acetaminophen Suppositories suppositories, n.pl solid capsules made of materials that melt at body temperature and are used to deliver medicinal substances into the rectum. in 120 mg., 325 mg. 650 mg. strengths were received by the Company. Acetaminophen Suppositories are the generic equivalent of the branded Acetaminophen Uniserts products which have a branded market of approximately $5 million. A.L. Pharma is a multinational pharmaceutical company developing, manufacturing and marketing specialty generic and proprietary human pharmaceuticals and animal health products. A.L. Pharma resulted from the combination of the human pharmaceutical and animal health businesses of Apothekernes Laboratorium A.S of Oslo, Norway with A.L. Laboratories, Inc. on October 3, 1994. CONTACT: A.L. Pharma Inc. Iris D. Daniels 201/947-7774 or Morgen-Walke Associates Inc. Investors: Donna Stein/Sue Rodney Press: Michelle Zawrotny 212/850-5600 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion